In a report released today, Madhu Kumar from B.Riley FBR reiterated a Hold rating on Arrowhead Research (NASDAQ: ARWR), with a price target of $18. The company’s shares closed yesterday at $15.10, close to its 52-week high of $17.50.
According to TipRanks.com, Kumar is a 5-star analyst with an average return of 28.2% and a 52.4% success rate. Kumar covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Arbutus Biopharma Corporation, and Deciphera Pharmaceuticals Inc.
Currently, the analyst consensus on Arrowhead Research is a Strong Buy with an average price target of $19.33.
See today’s analyst top recommended stocks >>
The company has a one-year high of $17.50 and a one-year low of $1.72. Currently, Arrowhead Research has an average volume of 2.03M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Arrowhead Pharmaceuticals, Inc. engages as a biopharmaceutical company developing targeted RNAi therapeutics. Its pipeline includes clinical programs in chronic hepatitis B virus and partner based programs in obesity and oncology. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.
Read More on ARWR:
